IRS Calls Mylan Patent Deal A 'License' In $100M Tax Fight
The IRS slammed Mylan Pharmaceuticals' contention that its $400 million patent deal with Forest Laboratories was a sale rather than a license for tax purposes, telling the U.S. Tax Court that...To view the full article, register now.
Already a subscriber? Click here to view full article